|Bid||0.5650 x 2000|
|Ask||0.5700 x 900|
|Day's Range||0.5500 - 0.5900|
|52 Week Range||0.2300 - 6.6000|
|Beta (3Y Monthly)||-3.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 8, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
CORAL GABLES, FL / ACCESSWIRE / December 6, 2018 / Analyst firms like Global Market Insights are expecting a lot as far as the future of healthcare is concerned. The firm reports that the healthcare industry ...
Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive care, today announced a strategic expansion for its intranasal betahistine development program. In two related transactions, the Company has acquired an Orphan Drug Designation for betahistine in the treatment of obesity associated with Prader-Willi syndrome (PWS) and signed a binding letter of intent to in-license exclusive rights to two US Patents relating to the use of betahistine for the treatment of depression and attention-deficit / hyperactivity disorder (ADHD), respectively.
With Thanksgiving behind us here's a few biotech/ healthcare companies that might be worth looking at before after your meal HENDERSON, NV / ACCESSWIRE / November 26, 2018 / Today we are highlighting: ...
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / November 21, 2018 / It was a day of gains for biotech stocks Auris Medical Holding and Bioblast Pharma after the companies announced positive developments. Bioblast announced it has executed a definitive agreement to acquire Enlivex Therapeutics while Auris Medical announced the results of a Pre-IND meeting with the FDA. Auris Medical Holding AG shares were up nearly 36% on Tuesday on roughly 13.7 million shares traded.
Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive care, today announced the results of its pre-Investigational New Drug (pre-IND) meeting with the United States Food & Drug Administration (FDA), where the FDA addressed the Company's questions and provided guidance on its AM-201 program with intranasal betahistine for the prevention of olanzapine-induced weight gain. In its written response, the FDA supported the planned conduct of a multiple dose Phase 1 trial with AM-201 administered to healthy subjects in combination with olanzapine to evaluate the pharmacokinetics, pharmacodynamics, and safety, and to establish proof-of-concept.
On a per-share basis, the Zug, Switzerland-based company said it had a loss of 14 cents. The company's shares closed at 63 cents. A year ago, they were trading at $7.39. _____ This story was generated ...
Positive outcomes from second Phase 1 trial with intranasal betahistine Further evidence for betahistine's preventive effects in antipsychotic-induced weight gain.
Zug, Switzerland, November 08, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical.
NEW YORK, NY / ACCESSWIRE / November 2, 2018 / U.S. markets rallied on Thursday, with the S&P 500 Index logging its first 3-day win streak in six weeks, as trade concerns between the U.S. and China continued ...
LONDON, Nov. 01, 2018 -- Auris Medical (EARS) is a clinical-stage biopharmaceutical company developing pharmacotherapies for neurologic disorders of the inner ear. The.
Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive care, today announced positive results from the second Phase 1 trial evaluating intranasal betahistine in healthy volunteers. The study results demonstrated superior bioavailability over a range of four intranasal betahistine doses compared to oral betahistine, with plasma exposure being 6 to 29 times higher (p-value between 0.056 and p
NEW YORK, NY / ACCESSWIRE / October 16, 2018 / Biotech stocks Auris Medical Holding and Agile Therapeutics were both seeing big gains on Monday. Traders are waiting for an update from Auris Medical on Wednesday while Agile recently concluded its formal dispute resolution with the FDA over the complete response letter issued for the new drug application of Twirla. Auris Medical Holding AG shares were skyrocketing on Monday with gains of 40.82% and an additional 23.19% in after-hours trading.
Auris Medical stock (NASDAQ:EARS) went gangbusters to kick off the week even though the company did not have any announcements or news surrounding it on Monday.
Zug, Switzerland, October 12, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical.
NEW YORK, NY / ACCESSWIRE / October 9, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
NEW YORK, NY / ACCESSWIRE / October 9, 2018 / No news from Auris Medical Holding yet shares were skyrocketing on Monday. The company has been on a rocket since announcing in late August feedback from a ...
On a per-share basis, the Zug, Switzerland-based company said it had a loss of 51 cents. The company's shares closed at 28 cents. A year ago, they were trading at $7.70. _____ This story was generated ...
LONDON, UK / ACCESSWIRE / July 13, 2018 / If you want a free Stock Review on OHRP sign up now at www.wallstequities.com/registration. For today, WallStEquities.com observes Auris Medical Holding AG (EARS), NewLink Genetics Corp. (NLNK), OHR Pharmaceutical Inc. (OHRP), and Omeros Corp. (OMER). The industry includes the manufacturing and marketing of drugs as a result of direct research and development.
On Tuesday, June 12, 2018, the NASDAQ Composite and the S&P 500 edged 0.57% and 0.17% higher, respectively at the closing bell, while the Dow Jones Industrial Average stayed bearish, finishing marginally lower by 0.01%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), Atara Biotherapeutics Inc. (NASDAQ: ATRA), Athersys Inc. (NASDAQ: ATHX), and Auris Medical Holding AG (NASDAQ: EARS).